1. Home
  2. PWUP vs IKNA Comparison

PWUP vs IKNA Comparison

Compare PWUP & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWUP
  • IKNA
  • Stock Information
  • Founded
  • PWUP 2021
  • IKNA 2016
  • Country
  • PWUP United States
  • IKNA United States
  • Employees
  • PWUP N/A
  • IKNA N/A
  • Industry
  • PWUP Blank Checks
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PWUP Finance
  • IKNA Health Care
  • Exchange
  • PWUP Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • PWUP 87.4M
  • IKNA 78.7M
  • IPO Year
  • PWUP 2022
  • IKNA 2021
  • Fundamental
  • Price
  • PWUP $11.25
  • IKNA $1.66
  • Analyst Decision
  • PWUP
  • IKNA Buy
  • Analyst Count
  • PWUP 0
  • IKNA 2
  • Target Price
  • PWUP N/A
  • IKNA $3.00
  • AVG Volume (30 Days)
  • PWUP 205.0
  • IKNA 323.5K
  • Earning Date
  • PWUP 01-01-0001
  • IKNA 08-08-2024
  • Dividend Yield
  • PWUP N/A
  • IKNA N/A
  • EPS Growth
  • PWUP N/A
  • IKNA N/A
  • EPS
  • PWUP 0.18
  • IKNA N/A
  • Revenue
  • PWUP N/A
  • IKNA $3,848,000.00
  • Revenue This Year
  • PWUP N/A
  • IKNA N/A
  • Revenue Next Year
  • PWUP N/A
  • IKNA N/A
  • P/E Ratio
  • PWUP $62.50
  • IKNA N/A
  • Revenue Growth
  • PWUP N/A
  • IKNA N/A
  • 52 Week Low
  • PWUP $10.07
  • IKNA $1.02
  • 52 Week High
  • PWUP $13.70
  • IKNA $6.80
  • Technical
  • Relative Strength Index (RSI)
  • PWUP 42.95
  • IKNA 50.15
  • Support Level
  • PWUP $11.26
  • IKNA $1.60
  • Resistance Level
  • PWUP $11.69
  • IKNA $1.78
  • Average True Range (ATR)
  • PWUP 0.00
  • IKNA 0.06
  • MACD
  • PWUP 0.00
  • IKNA -0.00
  • Stochastic Oscillator
  • PWUP 0.00
  • IKNA 33.52

About PWUP PowerUp Acquisition Corp.

PowerUp Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: